IP Library › Granted Patent US 12,054,735
Granted Patent B2
US 12,054,735 · App. 16/714,516 · Granted Aug 6, 2024

Viral vector production system

Inventors: Daniel Farley (Oxford, GB); Kyriacos Mitrophanous (Oxford, GB)
Assignee: Oxford BioMedica (UK) Limited
C12N15/86C12N7/00C12N2710/10343C12N2710/10351C12N2740/15043C12N2740/15051C12N2740/15052C12N2740/16043C12N2740/16051C12N2750/14143C12N2750/14151C12N2840/102C12N2840/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,054,735
App. No.
16/714,516
Granted
Aug 6, 2024
Kind
B2
Abstract

The present invention relates to a nucleic acid sequence comprising a binding site operably linked to a nucleotide of interest, wherein the binding site is capable of interacting with an RNA-binding protein such that translation of the nucleotide of interest is repressed in a viral vector production cell.

Claims (13)

1. A nucleic acid sequence comprising an RNA-binding protein (RBP) binding site operably linked to a nucleotide of interest (NOI), wherein the RBP binding site is capable of interacting with an RBP such that translation of the NOI is repressed in a viral vector production cell, wherein the RBP is heterologous to the NOI, and wherein the RBP is tryptophan RNA-binding attenuation protein (TRAP).

2. The nucleic acid sequence of claim 1 , wherein the TRAP binding site comprises multiple repeats of the sequence RAGN 2-3 .

3. The nucleic acid sequence of claim 2 , wherein the number of RAGNNN repeats is 1 or less.

4. The nucleic acid sequence of claim 2 , wherein the TRAP binding site comprises at least 8-11 repeats of the sequence RAGN 2 .

5. The nucleic acid sequence of claim 2 , wherein the TRAP binding site comprises 11 repeats of the sequence RAGN 2-3 , wherein the number of RAGNNN repeats is 3 or less.

6. The nucleic acid sequence of claim 1 , wherein the NOI encodes a therapeutic protein.

7. A viral vector comprising the nucleic acid sequence of claim 1 .

8. The viral vector of claim 7 , comprising a second NOI.

9. The viral vector of claim 7 , which is a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a herpes simplex viral vector, a vaccinia viral vector, or a baculoviral vector.

10. The viral vector of claim 7 , which is a lentiviral vector.

11. A cell transduced by the viral vector of claim 7 .

12. A method of identifying a nucleic acid binding site and/or a nucleic acid binding protein, the method comprising analysing expression of the NOI in a cell comprising the nucleic acid sequence of claim 1 and a nucleic acid sequence encoding the RBP, wherein the NOI is a reporter gene.

13. A method of repressing translation of a nucleotide of interest (NOI) in a viral vector production cell, the method comprising introducing into the viral vector production cell the nucleic acid sequence of claim 1 and a nucleic acid sequence encoding an RNA binding protein (RBP), wherein the RBP binds to the RBP binding site, thereby repressing translation of the NOI.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2019
From: FARLEY, DANIEL; MITROPHANOUS, KYRIACOS
To: OXFORD BIOMEDICA (UK) LIMITED
Reel/Frame 051304/0860 →
Priority Claims (1)
GB 1322798 · Dec 20, 2013 · national
Continuity (2)
Division 15106555
Related Publication 20200102578A1 · Apr 2, 2020